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Abstract Malaria is a worldwide disease caused by Plas-
modium parasites. A sesquiterpene endoperoxide artemisi-
nin isolated from Artemisia annua was discovered and has
been accepted for its use in artemisinin-based combinato-
rial therapies, as the most effective current antimalarial
treatment. However, the quantity of this compound pro-
duced from the A. annua plant is very low, and the avail-
ability of artemisinin is insufficient to treat all infected
patients. In addition, the emergence of artemisinin-resistant
Plasmodium has been reported recently. Several techniques
have been applied to enhance artemisinin availability, and
studies related to its mode of action and the mechanism of
resistance of malaria-causing parasites are ongoing. In this
review, we summarize the application of modern tech-
nologies to improve the production of artemisinin,
including our ongoing research on artemisinin biosynthetic
genes in other Artemisia species. The current understand-
ing of the mode of action of artemisinin as well as the
mechanism of resistance against this compound in Plas-
modium parasites is also presented. Finally, the current
situation of malaria infection and the future direction of
antimalarial drug development are discussed.
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Introduction
As a worldwide disease, malaria has been one of the main
cause of illness and death in humans for over a century,
especially in sub-Saharan Africa and Southeast Asia. More
than 200 million cases of malaria are reported every year;
in 2015, there were 214 million cases and 438,000 related
deaths [1]. This disease is caused by five species of Plas-
modium parasites: P. falciparum, P. vivax, P. malariae,
P. ovale, and P. knowlesi. Among these, P. falciparum is
the major cause of malaria infection in Africa, and P. vivax
is the most widely distributed malaria-causing parasite
globally [1]. Several antimalarial drugs have been devel-
oped since the seventeenth century. However, malaria-
causing parasites have developed resistance to these con-
ventional drugs, leading to treatment failure.
In response to the urgent need for new antimalarial
drugs, Chinese scientists Professor Youyou Tu and her
research group discovered artemisinin, the most effective
antimalarial drug derived from Artemisia annua in 1971
[2]. Artemisinin is a sesquiterpene lactone with an
endoperoxide bridge, which is necessary for antimalarial
activity during multiple stages of parasite development
[3–7]. Owing to its rapid action and high effectiveness
against malaria, the combination of artemisinin derivatives
and other antimalarial drugs, so-called artemisinin-based
combination therapies (ACTs), has been recommended as
the first-line treatments against malaria since 2006 [8].
ACTs have become the most powerful strategy to prevent
malaria and related deaths. Professor Tu was then awarded
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the Nobel Prize in Physiology or Medicine in 2015 for the
discovery of this effective antimalarial compound.
The demand for ACTs increases dramatically each year;
yet, the production yield of artemisinin fromA. annua is very
low and varies widely from 0.01 to 2 % dry weight [9].
Alternative approaches, including plant breeding technolo-
gies, synthetic biology, and total and semi-syntheses of
artemisinin, have been investigated to enhance the produc-
tion and reduce the cost of this compound. In addition, the
recent emergence of artemisinin-resistant Plasmodium par-
asites has also become a new challenge to scientists in the
elucidation of themechanism of resistance and identification
of the new strategies for malaria treatment.
In this review, we summarize recent studies on the
enhancement of artemisinin production and on artemisinin
biosynthetic genes in other Artemisia species, conducted in
our laboratory. In addition, the current understanding of the
mode of action of artemisinin against malaria-causing
parasites and, in turn, the mechanism of resistance of the
parasites to this compound are also presented. Finally, the
current situation of malaria infection and future directions,
including ongoing studies on antimalarial drug develop-
ment, are discussed.
Discovery of artemisinin
Before the discovery of artemisinin, powder derived from
cinchona tree bark had been used to treat malaria since the
seventeenth century. The active compound from this plant,
quinine, was first isolated in 1820 and was used as the only
effective antimalarial compound until the 1920s. The qui-
nine derivative chloroquine was developed as a new
effective antimalarial drug once quinine-resistant Plas-
modium strains appeared. During that time, the insecticide
DDT was widely used to control the spread of infected
mosquitoes as well. However, in the 1960s, increasing of
chloroquine-resistant Plasmodium strains and DDT-resis-
tant mosquitoes became a critical sign of the failure of
malaria prevention and treatment [10].
In response to the urgent need for new antimalarial
drugs, the Chinese government launched a national project
against malaria called Project 523 in 1967 [2]. The group,
led by Professor Youyou Tu, investigated more than 2000
Chinese herbs used as traditional Chinese medicines to
treat fever. Among these herbs, an extract from A. annua
showed highly effective inhibition against growth of
malaria-causing parasites. The active antimalarial compo-
nents were then extracted from the leaves of mature plants
in 1971 [2, 10–12]. After purification, the active anti-
malarial compound, named qinghaosu or artemisinin, was
obtained as colorless needle-like crystals. Its stereochem-
istry and chemical and X-ray crystal structures were
determined and reported several years later [2, 10, 11, 13].
Clinical trials involving either a non-toxic A. annua extract
or pure artemisinin have been conducted since 1972 by
several groups, and all patients in these trials quickly
recovered from the disease [11, 12]. These results clearly
indicated that artemisinin is an effective antimalarial
compound with rapid action and low toxicity.
Despite showing effective antimalarial activity, the low
solubility of artemisinin in both oil and water becomes a
therapeutic limitation of this compound. To address this
problem, many scientists have developed semi-synthetic
drugs and synthesized artemisinin derivatives with higher
solubility. Some of these artemisinin derivatives, which
have been used until the present, include dihy-
droartemisinin, artemether, and artesunate [14]. In addi-
tion, the combination of artemisinin or its derivatives with
other conventional antimalarial drugs greatly increased the
parasite clearance rate in patients and was first recom-
mended as a new strategy for malaria treatment in 1984
[15]. This strategy, known as ACT, has been recommended
by the World Health Organization (WHO) as a first-line
treatment for malaria to prevent recurrence and develop-
ment of resistance in malaria-causing parasites, whereas
the monotherapy is considered as an inappropriate treat-
ment [2, 8, 13, 14, 16].
Biosynthesis of artemisinin and expression pattern
of artemisinin biosynthetic genes in A. annua
A precursor of artemisinin, farnesyl pyrophosphate (FPP,
C15), is synthesized from two C-5 isoprenoid units derived
from the cytosolic mevalonate (MVA) pathway and one
isoprenoid unit derived from the non-mevalonate (MEP or
DXP) pathway [17, 18]. FPP is cyclized to amorpha-4,11-
diene by amorpha-4,11-diene synthase (ADS) [19–21] via
the generation of bisabolyl and 4-amorphenyl cation inter-
mediates [22, 23] (Fig. 1). The following step is the oxida-
tion of amorpha-4,11-diene to artemisinic alcohol by
amorpha-4,11-diene 12-monooxygenase (CYP71AV1)
[24]. This enzyme also catalyzes the oxidation of artemisinic
alcohol to artemisinic aldehyde and artemisinic acid. In
addition, alcohol dehydrogenase 1 (ADH1) and aldehyde
dehydrogenase 1 (ALDH1) also show specific oxidation
activity on artemisinic alcohol into artemisinic aldehyde and
on artemisinic aldehyde into artemisinic acid, respectively
[25, 26].Artemisinic acidwas thought to be the last precursor
of artemisinin. However, it has been revealed that this
compound is converted non-enzymatically into arteann-
uin B and related compounds, rather than artemisinin [27].
The next step of artemisinin biosynthesis is the reduction of
artemisinic aldehyde into dihydroartemisinic aldehyde by
artemisinic aldehyde D11(13) reductase (DBR2) [28]. Then,
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ALDH1 oxidizes dihydroartemisinic aldehyde into dihy-
droartemisinic acid, which is converted non-enzymatically
into artemisinin [26, 29], as shown in Fig. 1. Ryde´n et al. [30]
discovered dihydroartemisinic aldehyde reductase 1
(RED1), which reduces dihydroartemisinic aldehyde into
dihydroartemisinic alcohol. Although the role of RED1 in
artemisinin biosynthesis is still unclear, it has been suggested
that the silencing of RED1 might increase the production of
artemisinin in A. annua.
Artemisinin is produced mainly in glandular secretory
trichomes (GSTs) and its accumulation level declines as
plants mature. Olofsson et al. [31] showed that GSTs of
A. annua are found in all aerial tissues of plants, but not in
roots or hairy roots. The density of GSTs is highest in
flower buds and young leaves and decreases as leaves age.
The expression pattern of genes involved in the arte-
misinin biosynthetic pathway has been investigated
extensively for over a decade. The expression of genes in
the upstream pathway shows no correlation with the den-
sity of GSTs or the accumulation levels of artemisinin
intermediates [32]. In contrast, the expression of genes in
the downstream pathway is consistent with the density of
GSTs in each tissue. The expression of ADS is highest in
GSTs, high in flower buds and young leaves, low in stems,
negligible in old leaves and hairy roots, and not detected in
roots [31, 33–37]. CYP71AV1, DBR2, and ALDH1 showed
similar expression patterns: highest in GSTs and very low
in stems and roots. In hairy roots, the expression levels of
CYP71AV1 and DBR2 are relatively low, but the expres-
sion of ALDH1 is negligible [24, 26, 28, 31]. The expres-
sion levels of CYP71AV1 and DBR2 in leaves and flowers
show similar patterns, as they are high in leaf primordia
and flower buds but decrease as leaves and flowers develop
[38–40]. The expression pattern of ALDH1 in leaves at
different stages is similar to those of CYP71AV1 and DBR2
[31]. Although there is no report on the expression level of
ALDH1 during different stages of flowering, this gene
shows higher expression in flowers than in leaves [26, 31].
The expression of RED1 is relatively low in flower buds,
young leaves, and stems. In contrast, the expression of this
gene is much higher in old leaves and roots than in young
leaves [30, 31]. Interestingly, the expression of RED1 is
approximately 50-fold higher in hairy roots compared with
old leaves. Nevertheless, the function of RED1 in hairy
roots has not been established [31].
The expression levels of ADS and ALDH1, as well as
their enzymatic activities in high-artemisinin-producing
and low-artemisinin-producing A. annua cultivars, show
no differences. Even though the expression levels of
CYP71AV1 in these two cultivars are similar, CYP71AV1
in a high-artemisinin-producing cultivar shows lower
enzyme activity, which is suitable for the change in
metabolic flux to dihydro-analogues and artemisinin pro-
duction [41]. In contrast, the activity of DBR2 in both
cultivars shows no significant difference, but the gene
encoding this enzyme shows considerably higher expres-
sion levels in high-artemisinin-producing cultivars than in
low-artemisinin-producing cultivars [42].
Mode of action of artemisinin
Before artemisinin can exert its action, the endoperoxide
bridge has to be activated to generate the free radical
species. Two activation pathways of artemisinin have been
suggested, namely the mitochondrial and heme-mediated
degradation pathways [43]. Mitochondria-activated arte-
misinin is involved in lipid peroxidation inducing cyto-
toxicity via the generation of reactive oxygen species
(ROS) and depolarization of the parasite mitochondrial and
plasma membranes [43–47]. In the heme-mediated path-
way, two activation models (i.e., a reductive scission model
and an open peroxide model) have been proposed, both of
which lead to the generation of an active carbon-centered
radical [48]. Even though the non-heme Fe2? ion was
suggested to bind and activate artemisinin [7], recent
studies showed that heme plays a predominant role in
artemisinin activation rather than the Fe2? ion [5]. In
Plasmodium spp., heme is produced via endogenous heme
biosynthesis at the early ring stage and via hemoglobin
digestion at the trophozoite stage. However, the level of
bFig. 1 Summary of artemisinin biosynthesis, transgenic approaches
to enhance artemisinin production, and artemisinin mode of action.
The enzymes responsible for each reaction are indicated next to the
arrows. Suppression of competing pathways and artemisinin activity
and its targets are shown in bold. Transgenic approaches regulating
artemisinin production are shown in black boxes. Cyclization
mechanism of FPP to generate amorpha-4,11-diene is highlighted in
gray. Full names of intermediates and enzymes involved in the
pathway are as follows: HMG-CoA 3-hydroxy-3-methylglutaryl-
coenzyme A, G3P glycerol-3-phosphate, DXP 1-deoxy-D-xylulose
5-phosphate, MEP 2C-methyl-D-erythritol 4-phosphate, CDP-ME
4-diphosphocytidyl-2C-methyl D-erythritol, CDP-MEP CDP-ME
2-phosphate, MEC-PP 2C-methyl-D-erythritol 2,4-cyclodiphosphate,
HMB-PP (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate, IPP
isopentenyl pyrophosphate, DMAPP dimethylallyl pyrophosphate,
atoB (ERG10) acetoacetyl-CoA thiolase, HMGS (ERG13) HMG-CoA
synthase, HMGR HMG-CoA reductase, MK (EGR12) mevalonate
kinase, PMK (ERG8) phosphomevalonate kinase, MVD1 (ERG19)
mevalonate pyrophosphate decarboxylase, dxs DXP synthase, dxr
DXP reductase, ispD CDP-ME synthase, ispE CDP-ME kinase, ispF
MEC-PP synthase, ispG HMB-PP synthase, ispH HMB-PP reductase,
IDI IPP isomerase, FPS (ispA) farnesyl pyrophosphate (FPP)
synthase, SQS (ERG9) squalene synthase, ADS amorpha-4,11-diene
synthase, CYP71AV1 amorpha-4,11-diene 12-monooxygenase, CPR
cytochrome P450 reductase, ADH1 alcohol dehydrogenase 1, ALDH1
aldehyde dehydrogenase 1, DBR2 artemisinic aldehyde D11(13)
reductase, RED1 dihydroartemisinic aldehyde reductase 1 (color
figure online)
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heme biosynthesized endogenously in the parasites is much
lower than its production via hemoglobin digestion, sug-
gesting that hemoglobin-derived heme plays a major role in
artemisinin activation [5, 49]. Recently, Xie et al. [50]
reported that falcipains FP2a and FP3 (two main cysteine
protease hemoglobinases) are also involved in the potential
activation of artemisinin at an early ring stage.
After hemoglobin digestion, the heme detoxification
protein (HDP) can trigger the conversion of free heme to
hemozoin, which is essential for parasite survival [4, 51].
However, the formation of the artemisinin-free heme
complex shows an inhibitory effect on this conversion [51].
A translationally controlled tumor protein (PfTCTP) was
also reported as a potential target of artemisinin, as it could
form a covalent bond with this protein, resulting in protein
malfunction [52, 53]. Eckstein-Ludwig et al. [54] showed
that artemisinin specifically mediated the inhibition of
PfATP6, an orthologous sarco/endoplasmic reticulum
Ca2?-ATPase (SERCA), outside the food vacuole.
Recently, five enzymes involved in the key metabolic
pathways of the parasite were also reported as potential
targets of artemisinin, namely ornithine aminotransferase
(OAT), pyruvate kinase (PyrK), L-lactate dehydrogenase
(LDH), spermidine synthase (SpdSyn), and S-adenosyl-
methionine synthetase (SAMS). All of them are covalently
modified by the interaction with artemisinin, resulting in
the irreversible malfunction of enzyme activities [5].
Enhancement of artemisinin production
The demand for artemisinin increases every year. Even
though total synthesis of artemisinin from commercially
available chemicals or semi-synthesis from its intermedi-
ates have been reported, all of those methods are costly and
require several synthesis steps [55, 56]. In this review, we
summarize recent studies regarding four approaches to
enhance the production of artemisinin: (1) plant breeding
technologies, (2) overexpression of genes involved in the
artemisinin biosynthetic pathway, (3) direct or indirect
upregulation of artemisinin biosynthesis, and (4) heterol-
ogous production.
Plant breeding technologies
Conventional plant breeding techniques to select high-
artemisinin-producing cultivars have been used for dec-
ades. These techniques include cultivation of A. annua and
collection of cultivars with the desired properties. At pre-
sent, a robust hybrid A. annua is generated from the
combination of high-artemisinin-producing and vigorous
cultivars to increase the production yield of artemisinin to
more than 2 % dry weight [57–59]. Recently, an alternative
approach to increase the production of artemisinin from the
cultivation of high-artemisinic acid or dihydroartemisinic
acid-producing cultivars was proposed, since a method for
the semi-synthesis of artemisinin from these two precursors
has been developed [56, 60].
Scientists at the University of York used advanced
breeding techniques to evaluate the distribution of traits
that contribute to artemisinin yield [61]. From the screen-
ing of 23,000 strains, they succeeded in identifying genes
and molecular markers for fast-track breeding, enabling the
construction of a detailed genetic map of A. annua with
nine linkage groups. The established quantitative trait loci
(QTL) map is also applicable for rapid identification of
A. annua parental lines with useful traits for plant breed-
ing. Two hybrids, called Hybrid 1209r Shennong and
Hybrid 8001r Zenith, were developed with high artemisinin
productivity of up to 36.3 and 54.5 kg/ha, respectively. The
diallel cross approach to determine the combining ability of
the robust parental lines for the production of artemisinin
high-yielding A. annua hybrids was also developed by the
same group and showed consistent results with the QTL-
based molecular breeding approach [62].
Hairy root culture is another method to enhance the
production of secondary (specialized) metabolites, owing
to its rapid growth capabilities [63]. Transformation pro-
tocols to obtain hairy roots containing artemisinin from this
plant have been reported [64, 65]. In our laboratory, we
also attempted to establish the conditions for A. annua
hairy root cultivation. However, we still could not detect
even trace amounts of artemisinin or its intermediates from
the extract of hairy root cultures by GC–MS (unpublished
data). Artemisinin biosynthetic genes are highly expressed
in trichomes but almost negligible in root tissue
[31, 33–40], suggesting that the production of this com-
pound by hairy root cultures could be somewhat difficult.
Therefore, the most suitable conditions for hairy root cul-
tures to enhance production of artemisinin must be inves-
tigated. In addition, the identification of artemisinin
production from root extracts requires extreme care, and
NMR spectroscopic and mass spectrometric analyses are
required.
Overexpression of genes involved in artemisinin
biosynthetic pathway
Metabolic engineering of A. annua by overexpressing
genes involved in artemisinin biosynthesis has been given
more attention during the last 20 years. To obtain suc-
cessful transformants, several parameters for Agrobac-
terium tumefaciens-mediated transformation, such as the
concentration of antibiotics, method and duration of co-
cultivation, and phytohormones supplied for plant regen-
eration, have been optimized [66–71]. Among various
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explants available for transformation, stem internodes and
young inflorescence seem to be the most appropriate
[70–72]. Phytohormones a-naphthaleneacetic acid and
6-benzylaminopurine are crucial for GST development in
young leaves, and root generation also affects GST size
[73]. Recently, Kiani et al. [72] developed miniprep
methods using A. tumefaciens- and Agrobacterium rhizo-
genes-mediated transformation. This method exhibits
higher transformation rates with faster development of
transformants within 3–4 weeks compared with other
methods.
The overexpression of several genes involved in artemi-
sinin biosynthesis in A. annua has been evaluated. Overex-
pression of farnesyl pyrophosphate synthase (FPS) increased
artemisinin production up to 2- to 3.6-fold higher than that in
the control [74, 75]. Overexpressing CYP71AV1 and its
redox partner cytochrome P450 reductase (CPR) in artemi-
sinin biosynthesis could increase artemisinin content in
planta by 38 % [76]. Xiang et al. [77] generated dxr- and
CYP71AV1/CPR-overexpressing A. annua and found that
both transformants increased the production of artemisinin.
The overexpression of DBR2 increased the production of
artemisinin as well as its precursor dihydroartemisinic acid,
up to twofold, compared with non-transgenic plants. It also
increased production of artemisinic acid up to 5.48- to 9.06-
fold and arteannuin B up to twofold [78]. The reason why
overexpression of DBR2 enhanced biosynthesis of artemi-
sinic acid and arteannuin B has not been revealed. However,
Yuan et al. [78] hypothesized that excess dihydroartemisinic
acid might be converted into artemisinic acid in planta.
Overexpression of multiple genes involved in artemisi-
nin biosynthesis could greatly increase the production of
artemisinin in planta. Chen et al. [79] showed that the co-
overexpression of FPS, CYP71AV1, and CPR increased
artemisinin levels in A. annua up to 3.6-fold. The co-
overexpression of HMGR and FPS increased production of
artemisinin up to 1.8-fold higher than that in the control
[80]. Alam et al. [81, 82] co-overexpressed HMGR and
ADS in A. annua and found greatly increased artemisinin
levels, up to 7.65-fold, in this transgenic line.
Suppressing the expression of genes involved in the
pathways competing with artemisinin biosynthesis is
another approach to enhance artemisinin content in planta.
Zhang et al. [83] used RNAi techniques to suppress the
expression of SQS, the first committed gene in sterol
biosynthesis. The suppression of this gene enhanced the
production of artemisinin up to 3.14-fold.
Direct or indirect upregulation of artemisinin
biosynthesis
The effect of several stresses on production of artemisinin
in A. annua has been analyzed since the 1990s. These
stresses usually lead to the generation of ROS (required for
the last non-enzymatic step in artemisinin biosynthesis) or
upregulate the expression of artemisinin biosynthetic genes
[84–87]. Details of the stresses placed on artemisinin pro-
duction have been summarized previously [88, 89], and the
appropriate cultivation conditions of A. annua were sug-
gested [9].
Some transcription factors upregulated the expression of
artemisinin biosynthetic genes and promoted production of
artemisinin in A. annua. The WRKY1 transcription factor
is thought to bind to the W-box cis-acting elements of
promoters to promote gene expression. It is also involved
in the regulation of plant defense responses and develop-
mental and physiological processes. Ma et al. [33] showed
that the transcript levels of HMGR, ADS, CYP71AV1, and
DBR2 were induced in transient AaWRKY1-overexpressing
leaves. Furthermore, the specific overexpression of this
transcription factor in GSTs increased transcript levels of
CYP71AV1 up to 33-fold, compared with the wild type
[90]. AaORA, one of the APETALA2/ethylene response
factor (AP2/ERF) transcription factor involved in plant
responses to biotic and abiotic stresses, showed a similar
expression pattern to those of ADS, CYP71AV1, and DBR2.
The overexpression of this transcription factor led to the
upregulation of the expression levels of ADS, CYP71AV1,
and DBR2 in planta and promoted artemisinin production
[91]. Yu et al. [92] also reported the enhancement of
artemisinin production via overexpression of two tran-
scription factors from the same family, AaERF1 and
AaERF2, which bind to the promoter regions of ADS and
CYP71AV1. Another transcription factor that positively
regulates the biosynthesis of artemisinin is a basic helix-
loop-helix (bHLH) transcription factor, involved in meta-
bolic regulation of various hormones, developmental pro-
cesses, and regulation of light signaling, iron and
phosphate homeostasis, and various abiotic stresses [93].
Recently, Zhang et al. [94] reported that a basic leucine
zipper transcription factor (AabZIP1) binds to the ABA-
responsive elements (ABRE) of ADS and CYP71AV1
promoters and upregulates the expression of ADS,
CYP71AV1, DBR2, and ALDH1.
Several phytohormones upregulating artemisinin
biosynthesis have been reported. Treatment with salicylic
acid upregulates the expression of HMGR and ADS, as well
as induces ROS generation, driving the conversion of
dihydroartemisinic acid into artemisinin [95]. Methyl jas-
monate (MeJA) promotes the formation of GSTs and
enhances the expression of several genes involved in the
artemisinin biosynthetic pathway and related transcription
factors (ORA and ERF1), leading to the enhancement of
artemisinin production [96–98]. This phytohormone also
regulates trichome-specific fatty acyl-CoA reductase 1
(TFAR1), ABCG transporter unigenes (AaABCG6 and
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AaABCG7), and allene oxide cyclase (AaAOC)
[96, 99, 100]. TFAR1 is involved in the formation of
cuticular wax during GST expansion in A. annua.
AaABCG6 and AaABCG7 are ATP-binding cassette trans-
porter G, involved in the development of trichome cuticle
and may share a common regulatory system with ADS and
CYP71AV1. AaAOC is involved in JA biosynthesis. The
expression of this gene may be upregulated by treatment
with not only MeJA but also ABA and ethylene [100]. The
overexpression of the ABA receptor, AaPYL9, also
improves the sensitivity of ABA and promotes artemisinin
biosynthesis after ABA treatment [99, 101].
The enhancement of artemisinin production can be
achieved by increased GST density. Singh et al. [102]
reported that the expression of bgl1, encoding b-glucosi-
dase from Trichoderma reesei, in A. annua improved the
density of GSTs in flowers up to 66 % and increased the
production of artemisinin up to five-fold compared with the
control. The expression of rolB and rolC of A. rhizogenes
also increases GST density and upregulates the expression
of ADS, CYP71AV1, ALDH1, and TFAR1. Artemisinin
content is then increased 2- to 9-fold and 4-fold in rolB-
and rolC-expressing plants, respectively [103].
Co-cultivation of an endophytic fungus Piriformospora
indica and a nitrogen-fixing bacterium Azotobacter
chroococcum with A. annua increases artemisinin content
up to 70 % [104]. This dual symbiosis also shows a posi-
tive effect on plant height, dry weight, and leaf yield.
Another example of using symbiosis to increase the pro-
duction of artemisinin was reported using Glomus mosseae
and Bacillus subtilis [105]. Although clear evidence for the
effect of this symbiosis on the enhancement of artemisinin
production is still unknown, Arora et al. [104] suggested
that it might be due to improved growth and nutrient status
of the plant.
Heterologous production
Metabolic engineering of several platforms, such as Nico-
tiana benthamiana or chloroplasts, has been conducted.
Although ADS and CYP71AV1 were introduced into
N. benthamiana, the production of artemisinic acid 12-b-
diglucoside, instead of artemisinic acid, was detected at
39.5 mg/kg fresh weight (FW) [106]. The production yield
of artemisinic acid in tobacco chloroplasts was also very
low (0.1 mg/g FW) [107].
The production of plant natural compounds in
microorganisms is an alternative approach with several
advantages. The metabolic pathways in microorganisms
could be modified to produce various types of natural
compounds, including isoprenoids, alkaloids, and phenyl-
propanoids. Microorganisms can grow rapidly, allowing
shorter production time compared with the biosynthesis of
desired natural compounds in plants. Scaling up production
to industrial scale is also possible [108].
The production of artemisinin precursors in microor-
ganisms was first reported in 2003. Martin et al. [109]
expressed entire genes encoding the MVA pathway from
yeast Saccharomyces cerevisiae in Escherichia coli to
increase the intracellular concentration of FPP. To prevent
the rapid loss of highly volatile amorpha-4,11-diene during
culturing, the culture media was overlaid with dodecane to
trap amorpha-4,11-diene, referred to as a two-phase parti-
tioning bioreactor. As a result, they recovered the volati-
lized amorpha-4,11-diene, improving production titers
from 24 mg/L to approximately 500 mg/L in a fed-batch
bioreactor [110].
The coexpression of MevT operon with extra copies of
HMGR reduced the accumulation of toxic HMG-CoA and
increased production of mevalonate by threefold [111]. The
replacement of lac by lacUV5 promoter with a codon-op-
timized MevT and an additional copy of MK also led to the
increase in artemisinin production [112]. Tsuruta et al.
[113] succeeded in enhancing amorpha-4,11-diene pro-
duction in E. coli up to 27.4 g/L by replacing yeast HMGS
and HMGR with the equivalent enzymes from gram-posi-
tive bacteria Staphylococcus aureus.
Engineering of the MEP pathway and membrane efflux
transporters to improve the production of amorpha-4,11-
diene in E. coli has been reported as well [114–117].
However, there are many issues regarding the expression of
membrane-bound cytochrome P450s in this bacterium
posing a limitation on the production of the subsequent
oxidized compounds. To overcome these problems, Chang
et al. [118] engineered the N-terminal transmembrane do-
main of the codon-optimized CYP71AV1 and coexpressed
it with CPR from A. annua. As a result, production of
artemisinic acid (105 mg/L) in this E. coli strain was
obtained. Two years later, the same group replaced
CYP71AV1 by engineered P450 from gram-positive bac-
teria Bacillus megaterium (P450BM3) and could produce
artemisinic-11S,12-epoxide at higher than 250 mg/L suc-
cessfully [119]. From this finding, a novel semi-biosyn-
thetic route for the production of artemisinin stemming
from the cleavage of this epoxide followed by several
oxidation steps was proposed.
Yeast is another attractive host for the production of
artemisinin precursors as it produces FPP for sterol
biosynthesis via the MVA pathway. Since the MVA
pathway in S. cerevisiae has been characterized, ADS was
introduced into this yeast, and an amorpha-4,11-diene-
producing yeast strain was generated successfully [120].
While there are many issues concerning the expression of
cytochrome P450s in E. coli, the expression of this gene in
yeast is much more feasible. Therefore, CYP71AV1 and
CPR were coexpressed, and all genes involved in the MVA
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pathway were upregulated either directly or indirectly. The
competing pathway (sterol biosynthetic pathway) was also
downregulated using a methionine-repressible promoter to
improve the production of artemisinic acid in the yeast
expression system. As a result, this transgenic yeast strain
produced artemisinic acid at up to 100 mg/L [121, 122].
Several factors were further optimized for the production
of artemisinic acid in an industrial fermenter. For example,
the carbon source for growing yeast in a fermenter was
switched from glucose to galactose, and the oxygen
transfer rate was controlled. With this development, called
the galactose fed-batch process controlled by the DO-stat
algorithm, the artemisinic acid titer increased to 2.5 g/L
[123].
Despite conferring a higher production yield of artemi-
sinic acid, the use of galactose is costly and not applicable,
especially in developing countries. Thus, lower-cost
chemicals are needed as carbon sources. Yeast with GAL1,
GAL7, GAL10, and GAL80 deletions was generated to
exclude the use of galactose, and ethanol was alternatively
used as a carbon source. Two additional copies of truncated
HMGR (tHMG1) were integrated into this yeast strain. As a
result, the production of amorpha-4,11-diene was increased
up to more than 40 g/L [124]. Further development was
performed by the introduction of artemisinin biosynthetic
genes, CYP71AV1, CPR, ADH1, and ALDH1, to oxidize
amorpha-4,11-diene into artemisinic acid. Cytochrome b5
(CYB5) was also introduced into this strain as it can
accelerate cytochrome P450 reactions [125]. High-level
production of artemisinic acid, at 25 g/L, was thereby
achieved. The semi-synthesis of artemisinin from artemi-
sinic acid was also optimized, and the overall yield after
purification increased to 40–45 % [126, 127]. A potent
coupled chromatography–crystallization method to purify
artemisinin was then developed, and the recovery yield of
this antimalarial compound from the reaction mixture
increased to 61.5 %, with 99 % purity [128]. All of the
transgenes and modifications to several heterologous hosts
mentioned here are summarized in Table 1.
Artemisinin biosynthetic genes in non-artemisinin-
producing Artemisia species
Some studies reported that artemisinin is produced in other
Artemisia species [129–134]. However, we attempted to
isolate artemisinin from other Artemisia species but failed
to detect any trace amounts of artemisinin or its interme-
diates (unpublished data). Thus, we analyzed the expres-
sion of genes highly homologous to artemisinin
biosynthetic genes in these species. Firstly, we selected
A. afra and A. absinthium as they are widely cultivated in
Africa and exhibit anti-plasmodial activity [135–138].
Putative ADS orthologs were not expressed in either
A. afra or A. absinthium [139]. However, we detected the
expression of putative CYP71AV1 orthologs in both spe-
cies. Functional analysis revealed that these orthologous
enzymes show similar catalytic activities to their corre-
spondent in A. annua on the oxidation of amorpha-4,11-
diene into artemisinic acid [139]. We also detected the
expression of DBR2 ortholog in A. absinthium, and the
encoded enzyme showed comparable activity to that of
A. annua DBR2 [140]. In addition, we showed that this
plant can convert the fed artemisinin intermediates into the
following products along the biosynthetic pathway of
artemisinin [140]. Our findings suggest that ADS might be
a limiting factor for the production of artemisinin in planta,
and A. absinthium could be an alternative host for arte-
misinin production. The introduction of ADS into A. ab-
sinthium might lead to the generation of artemisinin-
producing A. absinthium, which could be used as an
alternative approach to produce artemisinin in other Arte-
misia species. To prove this hypothesis, this research is
now ongoing in our laboratory.
Next challenge: artemisinin-resistant Plasmodium
parasites
Artemisinin is the most effective antimalarial drug and has
been used as an ACT to treat malaria for over a decade.
However, the emergence of artemisinin-resistant Plas-
modium parasites in Southeast Asia, prolonging the para-
site clearance rate in patients, has been reported recently
and has become a critical issue [141–144]. No correlation
between resistance and other previously proposed candi-
date targets of artemisinin (PfATP6 and PfTCTP) was
detected [145]. However, it has been suggested that the
resistance occurs predominantly during the early ring stage
of parasite development as a result of the multiple forms of
mutations in the PF3D7_1343700 kelch propeller domain
(K13-propeller) on chromosome 13 [146–155]. K13-pro-
peller mutations lead to the increase of phosphatidylinosi-
tol-3-kinase (PfPI3K), which is required for the mediation
of cell signaling and survival [156, 157], and prolong
parasite development at the ring stage when the activation
level of artemisinin is rather low [5, 7, 158]. The B sub-
family of ABC transporters, known as multidrug resistance
proteins (MDR), also promotes artemisinin resistance. In
artemether–lumefantrine post-treatment infections, alleles
of Pfmdr1 tended to have 86N, 184F, and 1246D, rather
than the common YYY haplotype, and increased the
number of treatment failures [159]. The deletion of Pfmdr5
induced greater sensitivity to artemisinin treatment, sug-
gesting that this gene might contribute to artemisinin
resistance as well [160].
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Table 1 Heterologous production of artemisinin intermediates
Host No. Transgenes or modifications Product Yield References
N.
benthamiana








2 Prrn16S-atoB-HMGS-HMGR-MK-PMK-MVD1, PpsbA-E. coli IDI-FPS-
ADS-CYP71AV1-AaCPR
Artemisinic acid 0.1 mg/g FW [107]





4 Same as 3 but overlaid with dodecane Amorpha-4,11-
diene
500 mg/L [110]
5 PBAD-MevT, PBAD-tHMGR1 Mevalonate Threefold from
CTc
[111]
6 PlacUV5-MevT (codon opt.)-MBIS, Ptrc-ERG12 (codon opt.)-ADS Amorpha-4,11-
diene
293 mg/L [112]





8 PBAD-dxs-IDI-ispDF, ADS with Dpts and optimized medium Amorpha-4,11-
diene
182 mg/L [114]
9 PTM2-galP-glk, PT7-dxs-IDI-ispA-ADS Amorpha-4,11-
diene
201.2 mg/L [115]
10 AcrB, TolC (x2), ADS (codon opt.) Amorpha-4,11-
diene
404.83 mg/L [116]
11 PBAD-dxs-IDI-ispDF, ParaBAD-ADS, PTM1-macAB-TolC Amorpha-4,11-
diene
*30 mg/L/OD [117]
12 Same as 3 with CYP71AV1 (codon opt., engineered N-terminal
transmembrane)-AaCPR
Artemisinic acid 105 mg/L [118]




S. cerevisiae 14 PGAL1-ADS Amorpha-4,11-
diene
600 lg/L [120]
15 PGAL1-tHMGR PGAL1-upc2-1 erg9::PMET3-ERG9 PGAL1-tHMGR
PGAL1-ERG20, PGAL1-ADS PGAL10-CYP71AV1 PGAL1-AaCPR
Artemisinic acid 100 mg/L [121, 122]
16 Same as 15 with optimized culture condition Artemisinic acid 2.5 g/L [123]
17 gal80D::natr MAT a erg9D::kanr PMET3-ERG9, leu2-3,112::HIS
PGAL1-MVD1 PGAL10-ERG8 his3D1::HIS PGAL1-ERG12 PGAL10-
ERG10ade1D::PGAL1-tHMG1 PGAL10-IDI1 ADE1 ura3-52::PGAL1-














tHMG1PGAL10-ERG13hisG, trp1-289:: PGAL1- tHMG1PGAL10-
ERG20TRP1, ndt80D::PTDH1-HEM1HIS3PPGK1-CTT1,
gal80D::URA3PGAL7-AaADH1, [pAM552: 2l-LEU2d PGAL1-ADS
PGAL10-CYP71AV1]
Artemisinic acid 25 g/L [126, 127]
a MevT operon consists of atoB-HMGS-tHMGR
b MBIS operon consists ofERG12-ERG8-MVD1-IDI-ispA
c Production yield as compared to control (CT)
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Current situation of malaria infection and ongoing
studies on antimalarial drug development
Since ACTs have become the major treatment for malaria
and strict preventive measures against parasite-infected
mosquitoes have been implemented, the malaria-related
mortality rate and case incidence have decreased gradually
during the past 10 years [1]. Although artemisinin-resistant
Plasmodium parasites have emerged and show a significant
delay in clearance rate, the response of dihydroartemisinin
against either wild-type parasites or mutants exhibits sim-
ilar Km values suggesting that dihydroartemisinin does not
lose its activity against the mutants [161]. Extending the
treatment courses could be an effective strategy to clear
resistant parasite infection. However, the parasites can still
develop complete resistance against artemisinin-based
treatment at any point in the future. In addition, the pro-
portion of malaria-infected patients is concentrated in
countries with low national income levels. Among these,
more than 68 million infected children do not receive any
ACTs [1]. Therefore, large amounts of low-cost artemisinin
for ACTs, by either increasing the cultivation of high-
artemisinin-producing A. annua plants or developing
cheaper synthetic biological processes in the long term, are
required to prevent any further development of parasites
and meet the demand of ACTs worldwide. Moreover, novel
effective antimalarial treatments must be developed con-
tinually. Recently, low-cost plant-based artemisinin com-
bination therapy (pACT) has driven attention on the
production of no semi-synthetic artemisinin in planta as
this treatment showed higher antimalarial activity, and the
synergistic effect of artemisinin and the plant matrix
overcame resistance to artemisinin [162–169]. Several
scientists have also focused on the investigation of novel
potential drug targets [170–180] and on the synthesis of
novel antimalarial compounds including artemisinin
hybrids [181–186]. Still, further studies on these avenues
are required.
Conclusion
Several approaches to enhance the production of artemi-
sinin have been investigated for over a decade. As a result,
the availability of artemisinin for ACTs is increasing, and
the number of malaria-related deaths is decreasing gradu-
ally. Although artemisinin is still effective against malaria-
causing parasites, the emergence of artemisinin-resistant
strains has posed a new challenge to scientists worldwide.
Therefore, elucidating the mode of action of artemisinin
and the mechanism of resistance against this compound in
Plasmodium parasites is important for further development
of antimalarial drugs. We hope that the current under-
standing of artemisinin as summarized in this review will
provide clues for further investigation and development of
antimalarial treatments to overcome artemisinin resistance
in Plasmodium parasites in the future.
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